Nurix Therapeutics, Inc. Common stock Earnings Dividend

Nurix Therapeutics, Inc. Common stock’s revenue fell -66.12% since last year same period to $6.25Mn in the Q1 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated -53.95% fall in its revenue since last 3-months.

Nurix Therapeutics, Inc. Common stock’s net profit fell -54.7% since last year same period to $-87.17Mn in the Q1 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated -11.45% fall in its net profits since last 3-months.

Nurix Therapeutics, Inc. Common stock’s net profit margin fell -356.6% since last year same period to -1394.34% in the Q1 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated -142.02% fall in its net profit margins since last 3-months.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) estimates for the current quarter stand at -0.73 - a 12% jump from last quarter’s estimates.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) estimates for the current year stand at -0.73.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) fell -55.77% since last year same period to -0.81 in the Q2 2026. This indicates that the Nurix Therapeutics, Inc. Common stock has generated -55.77% annual rate of fall in its earning per share (EPS) in the last 4 quarters.